Olmesartan Studies Show “No Clear Evidence” Of CV Risk In Diabetes Patients, FDA Finds

Although data raise “concern of possible increased CV risk” with use of high-dose olmesartan in diabetic patients, FDA concludes that use of the drug in this group can continue.